20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety & tolerability of an
investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg
in subjects with sub-foveal neovascular AMD.